Melanoma Clinical Trials

Showing 921-940 of 1,292 trials

Study of Ipilimumab in the Immune System

NCT01715077

Participants will be taking 3 mg/kg ipilimumab intravenously over a 90-minute period every 3 weeks for a total of four doses. Tumor-infiltrating lymphocytes (TILs)will be analyzed for functional characteristics.

Previously Untreated and Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma

University Health Network, Toronto4 participantsStarted Oct 2012

Toronto, Ontario, Canada

WITHDRAWNPhase 1/2

Radiation Therapy With Combination Immunotherapy for Relapsed/Refractory Metastatic Melanoma

NCT03297463

This is a Phase 1b/2 study designed to evaluate combination of the human T-cell cytokine Interleukin-2 (IL-2) and a checkpoint inhibitor Ipilimumab immediately following a course of hypofractionated palliative radiation therapy in the management of unresectable, relapsed/refractory metastatic melanoma.

Metastatic MelanomaPulmonary MetastasesHepatic Metastases+1 more

Masonic Cancer Center, University of MinnesotaStarted Jan 2018

Minneapolis, Minnesota, United States

COMPLETEDPhase 2

Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma

NCT01673854

The purpose of this study is to assess the safety profile of vemurafenib, 960 mg, administered for 6 weeks, followed by ipilimumab monotherapy in patients with BRAF V600 mutated advanced/metastatic melanoma.

Melanoma

Bristol-Myers Squibb70 participantsStarted Sep 2012

Beverly Hills, California, United States • Jacksonville, Florida, United States • Orlando, Florida, United States +11 more locations

Study of Ipilimumab in the Immune System

Radiation Therapy With Combination Immunotherapy for Relapsed/Refractory Metastatic Melanoma

Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma

Related Searches

Quality of Life in Patients With Multimetastatic Melanoma Currently in Remission (QUALM)

A Study of Tasisulam-sodium Versus Paclitaxel as Treatment for Metastatic Melanoma

Tumor Cell Vaccines and ISCOMATRIX With Chemotherapy After Tumor Removal

Validation of MMS Test for Cancer Monitoring

An Observational Safety Study in Zelboraf (Vemurafenib)-Treated Patients With BRAF-V600 Mutation-Positive Unresectable or Metastatic Melanoma (ZeSS)

Phase 1 Study of GRN-1201 in HLA-A*02 Subjects With Resected Melanoma

Arsenic Trioxide in Treating Patients With Basal Cell Carcinoma

A Study of Tasisulam in Treating Participants With Malignant Melanoma

Feasibility Study of Genomic Profiling Methods and Timing in Tumor Samples

ML29255 Neoadjuvant Vemurafenib and Cobimetinib Melanoma

Bevacizumab and Temozolomide or Bevacizumab and Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed by Surgery

Diagnosing Melanoma, Squamous Cell Carcinoma and Basal Cell Carcinoma Using the Spectra-Scope

The Effectiveness of Nivolumab Monotherapy as First-Line Therapy in Adults With Advanced Melanoma in Germany

Dacarbazine and Carmustine in Metastatic Melanoma

Second Echelon Node Study With Methylene Blue

A Sunscreen Based on Bioadhesive Nanoparticles

Prospective, RCT of Split Thickness Skin Grafts on Lower Leg After Compression Therapy With Compression Bandage vs. NPWT